Men Need Your Help!

“To live an extraordinary life, you must resist an ordinary approach.”

The Portfolio

Our blog portfolio continues to perform well and volatility in the portfolio remains low vs the overall market. Year-To-Date the portfolio is up +17.62%. Our benchmark index, the S&P 500 is up 15.70% YTD.

Nabriva Therapeutics

On Monday Nabriva received a long awaited approval from the FDA for their drug Lefamulin in both oral and IV forms for the treatment of community-acquired pneumonia (CAP). As I mentioned in my last post, one of the unique risks in this space is that sometimes the stock price of a biotech will run up prior to an announcement and then sell off afterwards, even on good news. This is typically profit taking by traders and algorithmic trading platforms. Sometimes the opposite is true. Nabriva did see its stock price decline as traders took profits on the initial news. It's odd behavior as the company has now been substantially de-risked on this approval. Keep in mind that Nabriva was spun out of Novartis, the $204 billion dollar healthcare giant. Lefamulin should garner substantial market share for this important new antibiotic because its available in both oral and IV solutions. This means there is a substantial outpatient market for Lefamulin. Also on the horizon is legislation that will separate antibiotics for hard to treat conditions from everything else, allowing new comers like Nabriva to earn the true value of their drug from Medicare. While we didn't get the boost to the share price we wanted today, I suspect that investors will eventually come around and see the tremendous value in this company.

Men Need Your Help

For three years I've hosted a Distinguished Gentlemen's Ride in support of men's health. On Sunday the 29th of September, for the fourth year, I will don my finest attire with my fellow men and women across the globe to join the fight with The Distinguished Gentleman's Ride to raise awareness for prostate cancer and men's mental health. But before I press my tweed and polish my boots, I need you to donate what you can for this meaningful cause and help me reach my goal.

MY SPONSORSHIP PAGE

For your uncles, your brothers, your fathers and friends.

Donate what you can, for their lives need not end.

This year I'll be traveling to Ukiah, CA to support a new DGR Ride hosted by David and Martha Bookout. The DGR Ride is a program of the Movember Foundation. Movember seeks to make a global contribution to men living happier, healthier, longer lives. It is the driving force behind their campaigns, funding strategy, and vision for the future.

The state of men's health is in a crisis. By 2030 Movember aims to:

  • Reduce the number of men dying prematurely by 25%

  • Reduce the rate of male suicides by 25%

  • Halve the number of deaths from prostate cancer

  • Halve the number of men dying from testicular cancer

  • Halve the number of men experiencing serious mental and physical side effects from treatment for prostate cancer or testicular cancer

You can learn more at Charity Navigator: Movember Foundation

Earnings Season Catch Up

Most of our holdings have reported. To help you skim through the long list I've color coded the REPORTED titles as MISSED, IN-LINE or , BEATMIXED

VEEV 8-22-2019

EXPECTED: Veeva Systems Inc. is estimated to report earnings on 08/22/2019.

The consensus EPS forecast for the quarter is $0.49. Earnings range is range is $0.48 to $0.51.

The consensus revenue forecast for the quarter is $259.37M, Revenue range is $254.17M - $262.6M.

HEI 8-26-2019

EXPECTED: Heico Corporation is estimated to report earnings on 08/26/2019.

The consensus EPS forecast for the quarter is $0.54. Earnings range is range is $0.50 to $0.56.

The consensus revenue forecast for the quarter is $510.16M, Revenue range is $503.4M - $521.53M.

"Markets don't go to zero, Portfolio's do.

Buy quality, be patient...and look twice for motorcyclists"

- Clay Baker

Stay Invested,

Clay

ENTER YOUR NAME & EMAIL ADDRESS TO SUBSCRIBE

SUBSCRIBE HERE

Keep Me Honest

  1. S&P 500 declines to 2,350 or more (1-3-2019)

  2. Healthcare and Biotech sectors outperform (1-3-2019)

  3. S&P reaches 3,000 by year end (1-11-2019)

  4. CSCO reaches $60/share (1-18-2019)

  5. VEEV reaches $145/share (2-14-2019) (achieved $145.23 on 5-10-2019)

  6. CVS reaches $91.50 (2-27-2019)

  7. Bull market takes another leg up (4-7-2019)

  8. The Fed will lower rates 1-2 times (5-13-2019)

Clay's Rules

Rule #1: Don't lose money

Rule #2: See Rule #1

Rule #3: Portfolios go to zero, markets don't, Stay Invested

Rule #4: When a good stock you own drops 10% below your cost basis, add shares

Rule #5: Bull markets aren't sustained without the Transports

Rule #6: When Forward P/E is lower than TTM P/E, expect earnings to increase

Disclosure: I am personally invested long in some or all of these stocks or funds that appear in the Stay Invested portfolio and may purchase or sell shares within the next 72 hours. I am also invested in other stocks and funds that do not appear in the Stay Invested portfolio but may be mentioned or related to this article. It is not my intention to advise or encourage the purchase or sale of any security. I am invested long in these securities mentioned in this post:

CVS, CSCO, VEEV, STZ, AMZN, NVDA, BCRX, GS, BDSI, VEEV, VTI, GLD, HD, AWR, XLNX, MRVL, NBRV

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. This article is not intended to offer investing advice, guarantee 100% accurate predictions, or to be interpreted as providing a personal recommendation.

Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

This material is provided for informational purposes only, as of the date hereof, and is subject to change without notice.
This material may not be suitable for all investors and is not intended to be an offer, or the solicitation of any offer, to buy or sell any securities.

© 2016 by Clay Baker all rights reserved